NCT01379183 · ADVERSE EVENTS

Adverse events

Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility · Source last updated 2016-03-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Not reported
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Erythromycin Erythromycin 200 mg i.v. suspension	0 / 20	0 / 20	Not reported / Not reported
Placebo Matching placebo i.v. suspension	0 / 20	0 / 20	Not reported / Not reported

Group identifiers: EG000: Erythromycin · EG001: Placebo

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

description
Erythromycin 200 mg i.v. suspension
id
EG000
other Num Affected
0
other Num At Risk
20
serious Num Affected
0
serious Num At Risk
20
title
Erythromycin
description
Matching placebo i.v. suspension
id
EG001
other Num Affected
0
other Num At Risk
20
serious Num Affected
0
serious Num At Risk
20
title
Placebo

frequency Threshold

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice